In this disclosure, a method is described wherein the method comprises mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion; and administering the produced dispersion intravenously to a patient; wherein the prod
In this disclosure, a method is described wherein the method comprises mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion; and administering the produced dispersion intravenously to a patient; wherein the produced dispersion contains nanobubbles of the therapeutic gas or droplets of the therapeutic liquid with a mean diameter of less than about 1.5 μm. In this disclosure, a system is also described wherein the system comprises a therapeutic gas source or a therapeutic liquid source or a combination thereof; a liquid carrier source; a high shear device (HSD) having an inlet, an outlet, at least one rotor, and at least one stator separated by a shear gap; and a pump configured to control the flow rate and residence time of a fluid passing through the high shear device.
대표청구항▼
1. A method comprising: mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion, wherein said high shear device comprises at least one rotor and at least one complementarily-shaped stator; andadministering the prod
1. A method comprising: mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion, wherein said high shear device comprises at least one rotor and at least one complementarily-shaped stator; andadministering the produced dispersion intravenously to a patient;wherein the produced dispersion contains bubbles of said therapeutic gas or droplets of said therapeutic liquid, wherein said bubbles of said therapeutic gas or said droplets of said therapeutic liquid have a mean diameter of less than 1 nanometer. 2. The method of claim 1 wherein said therapeutic gas is selected from the group consisting of ozone, sulfur based gases, carbon monoxide, oxygen, hydrogen, nitrogen, an anesthetic gas, a noble gas, and mixtures thereof. 3. The method of claim 1 wherein said therapeutic liquid is selected from the group consisting of sulfur, a sulfate, an organo metallic, an antibiotic, a steroid, a vitamin, an organosulfur compound, allyl propyl disulfide, diallyl disulfide (DADS or 4,5-dithia-1,7-octadiene), allyl trisulfide (DATS), S-Allyl cysteine (SAC), a vinyldithiine, a sulfonyl compound, an antioxidant, a lipid, a chelating agent, and combinations thereof. 4. The method of claim 3 wherein said antioxidant comprises curcumin (turmeric); wherein said chelating agent comprises diethylene triamine pentaacetic acid (DTPA); wherein said vinyldithiine comprises 2-vinyl-[4H]-1,3-dithiine or 3-vinyl-[4H]-1,2-dithiine; wherein said organosulfur compound comprises allicin; and wherein said sulfonyl compound comprises ajoene. 5. The method of claim 1 wherein the therapeutic gas is selected from the group consisting of hydrogen, hydrogen sulfide, and oxygen. 6. The method of claim 1 wherein the therapeutic gas is oxygen, and the produced dispersion is utilized in conjunction with a blood substitute. 7. The method of claim 1 wherein a combination of therapeutic gases or a combination of therapeutic liquids or a combination of therapeutic gas and liquid is utilized. 8. The method of claim 1 wherein said liquid carrier comprises a total parenteral nutrition (TPN) solution. 9. The method of claim 1 wherein said liquid carrier comprises an enhancer for carrying said therapeutic gas or said therapeutic liquid. 10. The method of claim 1 further comprising incorporating a medicine into the produced dispersion prior to administering the dispersion to the patient. 11. A method of treating a disease comprising utilizing the method of claim 1 and utilizing an existing treatment method. 12. The method of claim 9 wherein the enhancer comprises tristearin. 13. The method of claim 1 wherein the high shear device is operated to provide a shear rate of greater than about 20,000 s−1. 14. The method of claim 1 wherein the produced dispersion comprises a cancer therapeutic. 15. The method of claim 1 wherein the therapeutic gas comprises an anesthetic.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (8)
Langer, Deborah A.; Westfall, David L.; Skoch, William E.; Mullay, John J., Continuous process for making an aqueous hydrocarbon fuel.
Deborah A. Langer ; David L. Westfall ; Morris E. Smith ; Robert T. Graf ; Harshida Dave ; John J. Mullay ; Daniel T. Daly ; Elizabeth A. Schiferl, Process and apparatus for making aqueous hydrocarbon fuel compositions, and aqueous hydrocarbon fuel composition.
Deborah A. Langer ; David L. Westfall ; Morris E. Smith ; Robert T. Graf ; Harshida Dave ; John J. Mullay ; Daniel T. Daly ; Elizabeth A. Schiferl ; Brian B. Filippini ; William D. Abraham, Process and apparatus for making aqueous hydrocarbon fuel compositions, and aqueous hydrocarbon fuel composition.
Deborah A. Langer ; David L. Westfall ; Morris E. Smith ; Robert T. Graf ; Harshida Dave ; John J. Mullay ; Daniel T. Daly ; Elizabeth A. Schiferl ; Brian B. Filippini ; William D. Abraham , Process and apparatus for making aqueous hydrocarbon fuel compositions, and aqueous hydrocarbon fuel compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.